A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544

Trial Profile

A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Influenza virus vaccine; Pneumococcal vaccine
  • Indications Agammaglobulinaemia; Chronic lymphocytic leukaemia; Influenza virus infections; Pneumonia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to discontinued due to slow accrual.
    • 07 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
    • 07 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top